Conference call and webcast to be held at 4:30 p.m. ETNEW HAVEN, Conn., March 10, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics ...
Mendelian randomization revealed a potential protective role of IPF against large artery atherosclerosis stroke, but no significant links with other cardiovascular diseases. The study suggests ...
Trevi Therapeutics (TRVI) advances Haduvio for IPF cough/RCC; Phase 2 IPF data strong, but funding, safety & opioid-label ...
Chronic fatigue is a common symptom of idiopathic pulmonary fibrosis (IPF), and may affect as many as 95 percent of all individuals living with this condition.Fatigue can have a significant impact on ...
The Company will conduct two Phase 3 clinical trials of nalbuphine ER for the treatment of patients with IPF-related chronic coughFirst pivotal ...
IPF patients showed reduced anxiety and depression scores one month post-COVID-19 vaccination, indicating improved mental health. The study emphasized the heightened COVID-19 risk for IPF patients, ...
Idiopathic pulmonary fibrosis (IPF) is a serious lung condition involving scar tissue inside your lungs that makes it hard to breathe. It is a progressive condition, which means that it gets worse ...
PureTech Health (PRTC) announced results from ELEVATE IPF, a Phase 2b randomized, double-blind, active- and placebo-controlled, dose-ranging trial evaluating deupirfenidone at two dose levels three ...
Abbvie (ABBV) announced an update on their ongoing clinical study.